
==== Front
Clin Res Cardiol
Clin Res Cardiol
Clinical Research in Cardiology
1861-0684
1861-0692
Springer Berlin Heidelberg Berlin/Heidelberg

37698619
2299
10.1007/s00392-023-02299-w
Original Paper
Catheter based left atrial appendage closure in-hospital outcomes in Germany from 2016 to 2020
http://orcid.org/0000-0003-0200-7495
Maier Alexander alexander.maier@uniklinik-freiburg.de

1
Kaier Klaus 2
Heidt Timo 1
Westermann Dirk 1
von zur Mühlen Constantin 1
Grundmann Sebastian 1
1 grid.5963.9 Department of Cardiology and Angiology, Faculty of Medicine, University Heart Center Freiburg-Bad Krozingen, University of Freiburg, Hugstetter Straße 55, 79106 Freiburg, Germany
2 https://ror.org/0245cg223 grid.5963.9 0000 0004 0491 7203 Institute of Medical Biometry and Statistics, Faculty of Medicine, University of Freiburg, Freiburg, Germany
12 9 2023
12 9 2023
2024
113 10 14191429
15 3 2023
29 8 2023
© The Author(s) 2023
2023
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Background

New and refined catheter based left atrial appendage (LAA) closure devices have been introduced in the past decade. The procedure can be performed using either an endocardial occlusion device or an epicardial loop stitch. We aimed to analyzed recent procedural safety.

Methods

Catheter based LAA closures were identified in a complete nationwide German dataset via ICD and OPS codes from 2016 to 2020.

Results

From 2016 to 2020, 28,039 endocardial and 213 epicardial occlusions were performed. Numbers of endocardial procedures increased from 5259 in 2016 to 5917 in 2020 (p = 0.020) in 387 centers with shifting of patients’ characteristics towards older age (β = 0.29, p < 0.001), more heart failure (β = 1.01, p < 0.001) and renal disease (β = 0.67, p = 0.001) and without a significant trend for in-hospital safety except more bleeding (β = 0.12, p = 0.05). In-hospital major adverse cardiac and cerebrovascular events (MACCE) or pericardial puncture were independent on center procedure numbers.

The loop stitch procedure was performed in 15 centers. Patients were younger (76.17 ± 8.16 vs. 73.16 ± 8.99, p < 0.001) and had a lower comorbidity index (2.29 ± 1.93 vs. 1.92 ± 1.64, p = 0.005). Adjusted risk difference for pericardial effusion (8.04%; 95% CI 3.01–13.08%; p = 0.002) and pericardial puncture (6.60%; 95% CI 3.85–9.35%; p < 0.001) was higher for the loop stitch procedure, while risk of bleeding (− 1.85%; 95% CI − 3.01 to − 0.69%; p = 0.002), intracerebral bleeding (− 0.37%; 95% CI − 0.59 to − 0.15%; p = 0.001) and shock (− 1.41%; 95% CI − 2.44 to − 0.39%; p = 0.007) was lower. No significant difference was observed for in-hospital MACCE.

Conclusions

Endocardial occlusion was the major catheter based LAA closure procedure in Germany without improvements in in-hospital safety from 2016 to 2020. In-hospital MACCE was independent on endocardial LAAC center volumes. Conclusions on the comparison between the two procedure types must be made cautious as the LAA loop stitch occlusion was utilized limited in a minor number of centers.

Graphical abstract

Catheter based left atrial appendage closure in-hospital outcomes in Germany from 2016 to 2020

Supplementary Information

The online version contains supplementary material available at 10.1007/s00392-023-02299-w.

Keywords

LAA closure
Left atrial appendage
In-hospital outcome
Germany
Universitätsklinikum Freiburg (8975)Open Access funding enabled and organized by Projekt DEAL.

issue-copyright-statement© Springer-Verlag GmbH Germany, part of Springer Nature 2024
==== Body
pmcIntroduction

The 2020 European Society of Cardiology Guidelines for the diagnosis and management of atrial fibrillation state left atrial appendage closure to be an option for stroke prevention therapy in patients with atrial fibrillation [1–3]. While there is excellent evidence that oral anticoagulation is recommended for stroke prevention in AF patients with CHA2DS2-VASc score ≥ 1 in men or ≥ 2 in women [1, 4], LAAC may be considered for stroke prevention in patients with known contraindications for such long-term anticoagulant treatment e.g. intracranial bleeding without a reversible cause [5–9].

Beside the surgical option to close the LAA, mainly two catheter based approaches are available today. One approach is LAAC through a permanently implanted endocardial occlusion device (e.g. Watchman, Boston Scientific or Amplatzer Amulet, Abbott). Here, the left atrial appendage is accessed via puncture of the interatrial septum through a venous catheter to place the device in the LAA, resulting in an exclusion of blood flow. The first Watchman and Amplatzer occluders were implanted in 2002. The Watchman occluder received its CE mark in Europe in 2005 [10] and the Amplatzer plug has a CE mark since 2008. After that newer device generations were introduced. FDA approval of endocardial LAA occluders started later beginning with the Watchman device in 2015. In general, higher safety event rates have been reported in real-world analyses [11–15] compared with industry-sponsored studies for these devices [16, 17].

Another, non-FDA-approved option is an epicardial loop stitch around the base of the LAA (Lariat, SentreHeart) [18]. It requires accessing the heart through both transseptal puncture and pericardial access by transthoracic puncture. Lariat was implanted for the first time in 2011 [19] and received the CE mark in 2015 [20]. After the FDA issued a safety alert in 2015 the procedure has been made safer [21, 22] and Lariat XT was released.

Overall, in-hospital complications remain an “Achilles heel” of interventional LAA occlusion. An update of in-hospital safety trends for catheter based LAAC is of particular interest since improvements in device design and new device generations were introduced and entered the clinical routine in the past years. New OPS codes in Germany made it possible to compare in-hospital safety of the permanently endocardial implanted LAA occlusion devices with the epicardial loop stitch procedure around the base of the LAA. In this study, we analyzed procedure numbers of the two available catheter-based LAAC approaches and in-hospital safety trends in the German nation-wide in-patient registry from 2016 to 2020. We additionally compared the in-hospital safety profile of the intracardiac implanted LAA occlusion device procedure with the loop stitch procedure around the LAA base.

Methods

Data source

Since 2005, the German Federal Bureau of Statistics (Statistisches Bundesamt, Destatis), through its Research Data Center, provides data on all inpatient stays in Germany. These data are based on inpatient hospital settlements according to the German Diagnosis Related Groups (DRG) system, which is based on fixed charge groups formed on the basis of diagnoses (coded according to ICD-10) and procedures performed [coded according to the German Operation and Procedure Classification (OPS)]. Upon prior request, the Research Data Centre can provide an analysis of your data in the form of fully anonymous, aggregated results, which will be published by the Research Data Centre. If necessary, partial results will be censored. Therefore, investigators only have access to summary results provided by the Research Data Center, an and do not have direct access to individual patient data. Therefore, approval by an ethics committee and informed consent were determined not to be required for our study, in accordance with German law. All of the summary results have been anonymized by the Research Data Centre. In practice, this means that, in order to guarantee data protection, the Research Data Centre censored any information that would allow conclusions to be drawn about an individual patient or a specific hospital.

Diagnoses and outcomes definitions

We requested data and numbers of patients that underwent the catheter-based transseptal and endocardial LAA occlusion procedure (OPS-code 8-837.s0) and the epicardial loop stitch procedure around the LAA base (8-837.s1) for each year from 2016 to 2020 from the German Research Data Center.

The following patient baseline characteristics were requested: Age, female sex, Charlson comorbidity index (see reference for complete ICD-10 list [23]), arterial hypertension (I10), atrial fibrillation (I480 1 2 9), heart failure NYHA III or IV (I5013 and I5014), coronary artery disease (I25), previous myocardial infarction (I252), previous cardiac surgery (Z951 2 3 4), peripheral vascular disease (I702 8 9 I739), carotid disease (I652), chronic obstructive lung disease (J44), pulmonary hypertension (I27), chronic renal disease (N18), diabetes (E10 1 2 3 4), cancer (ICD C*), surgery (OPS 5*).

The following in-hospital outcome parameters were requested for each year from 2016 to 2020: myocardial infarction (I21), stroke (I63), MACCE (composed of in-hospital mortality, myocardial infarction and stroke), bleeding (transfusion > 5 erythrocyte concentrates, 88800c1—8800cr and 880070—88007e), intracerebral bleeding (I61), pericardial effusion (I312 or I313), pericardial puncture (OPS 81520*), pericardiotomy (OPS 5370*), deep vein thrombosis (I80), tachycardia (I47 R000), shock (R57) and resuscitation (OPS 877*). In-hospital mortality and length of hospital stay were part of DESTATIS’ main set of variables.

Statistical methods

Categorical variables were presented as n (%). Continuous variables were summarized as mean ± SD. Pearson’s chi-square and t-tests were used to make descriptive comparisons between groups as appropriate. Temporal trends were observed using simple linear regression models.

Since patients were not randomized towards permanently implanted occlusion or a loop stitch procedure, potential confounding factors were taken into account using the propensity score methods. Thereby, inverse probability weighting was applied. The propensity score is defined as the conditional probability of an individual for being in the treatment group, given a group of observed covariates. For the propensity score estimations, we fit logistic regression models with the “teffects ipw” estimation procedures in Stata 17 and controlling for 18 predetermined covariates (all variables listed in Table 1 and Supplement Table 1). To determine the impact of procedure volumes on the endpoints MACCE and pericardial puncture, multivariable logistic regression analyses were performed. For risk adjustment, age, the Charlson Comorbidity Index and procedure volume were included as continuous covariates while all categorical characteristics listed in Table 2 were included as categorical covariates. Cluster-robust standard errors were used to account for the correlation of error terms of patients treated in the same hospital. Two-sided p-values are given, and statistical significance was considered as p-value < 0.05. No adjustments for multiple testing were done. All analyses were carried out using Stata 17 (StataCorp, College Station, Texas, USA). Table 1 Centers per year performing each LAA occlusion procedure from 2016 to 2020

Centers/year	2016	2017	2018	2019	2020	
N Centers endocardial implanted device	311	329	353	387	384	
N Centers loop stitch around LAA base	15	13	14	11	13	

Table 2 Baseline characteristics for patients implanted an endocardial LAA occlusion device or loop stitch around the LAA base from 2016 to 2020

Characteristic	Total procedure, n = 28,252	endocardial implanted LAA occlusion device, n = 28,039	loop stitch around the LAA base, n = 213	p	
Age (mean ± SD)	76.15 ± 8.16	76.17 ± 8.16	73.16 ± 8.99	 < 0.001	
Women	11,047 (39.10%)	10,952 (39.06%)	95 (44.60%)	ns	
Charlson Comorbidity Index	2.28 ± 1.78	2.29 ± 1.93	1.92 ± 1.64	0.005	
Arterial hypertension	16,756 (59.31%)	16,613 (59.26%)	143 (67.14%)	ns	
Atrial fibrillation	27,420 (97.06%)	27,216 (97.06%)	204 (95.77%)	ns	
CHA2DS2-VASc (mean ± SD)	4.00 ± 1.41	4.01 ± 1.41	3.79 ± 1.46	0.022	
Heart failure NYHA III or IV	5119 (18.12%)	5089 (18.15%)	30 (14.08%)	ns	
Coronary artery disease	12845 (45.47%)	12,752 (45.48%)	93 (43.66%)	ns	
Previous myocardial infarction	2200 (7.79%)	2193 (7.82%)	7 (3.29%)	0.014	
Previous cardiac surgery	3474 (12.30%)	3460 (12.34%)	14 (6.57%)	0.011	
Peripheral vascular disease	1998 (7.07%)	1988 (7.09%)	10 (4.69%)	ns	
Carotid disease	483 (1.71%)	481 (1.72%)	1–3 (≤ 1.41%)	–	
COPD	3519 (12.46%)	3022 (10.78%)	16 (7.51%)	ns	
Pulmonary hypertension	2351 (8.32%)	2339 (8.34%)	12 (5.63%)	ns	
Chronic renal disease	10,995 (38.92%)	10,921 (38.95%)	74 (34.74%)	ns	
Diabetes	8897 (31.49%)	8838 (31.52%)	59 (27.70%)	ns	
Cancer	587 (2.08%)	585 (2.09%)	1–3 (≤ 1.41%)	–	
LAA Left atrial appendage, SD standard deviation, NYHA New York Heart Association, COPD Chronic obstructive pulmonary disease

Results

Procedure and center numbers

From 2016 to 2020 a total number of 28,252 LAAC procedures were conducted in Germany. Among them, 28,039 used endocardial occlusion devices and 213 were loop stitch procedures around the LAA base via a pericardial access. While the number of centers performing the endocardial LAA occlusion increased from 311 in 2016 to 384 in 2020, the number of centers performing the epicardial loop stitch procedure around the LAA base was low between 11 and 15 centers (Table 1).

Patient characteristics

Patient characteristics of all patients from 2016 to 2020 are given in Table 2 and Supplemental Table 2. Patients receiving the endocardial implanted LAA plug were 76.17 ± 8.16 years, 39.06% were female. Cardiovascular and renal comorbidities were common in these patients as well as diabetes and COPD. Patients receiving the epicardial loop stitch around the LAA base were younger (p < 0.001) and less sick according to the Charlson comorbidity index (p = 0.005). According to the CHA2DS2-VASc Score they had a lower risk of thromboembolic stroke (p = 0.022). They had significantly less of a history of previous myocardial infarctions (7.82% vs. 3.29%, p = 0.014) or previous cardiac surgeries (12.34% vs. 6.57%, p = 0.011). Other comorbidities such as arterial hypertension, heart failure NYHA III or IV, peripheral vascular disease, COPD, pulmonary hypertension, renal disease, diabetes or cancer were similarly distributed in both groups.

5-year LAAC procedure number trends

The 5-year procedure numbers of both the endocardial implanted device and loop stitch procedure increased in total from 5307 in 2016 to 5952 in 2020 (β = 199.7, p = 0.021). The peak was reached in 2019 with 6019 procedures. From 2016 to 2020 annual procedure numbers of the loop stitch around the LAA base did not show a significant trend and remained very rare (lowest procedure number 35 in 2020, highest number 52 in 2018). The annual endocardial implanted LAA plug numbers increased from 5259 in 2016 to 5917 in 2020 (β = 0.203, p = 0.020, Fig. 1) peaking in 2019 with 5981 implantations.Fig. 1 Annual numbers of endocardial implanted LAA occlusion devices and loop stitch procedures around the LAA base in Germany from 2016 to 2020

5-year patient characteristic trends for endocardial implanted occlusion device

From 2016 to 2020 patient characteristics for the endocardial implanted LAA plugs changed slightly towards older age (β = 0.29, p < 0.001), a higher proportion of female patients (β = 0.46, p = 0.025), more heart failure patients (β = 1.01, p < 0.001) and a higher proportion of patients with renal disease (β = 0.67, p = 0.001) and cancer (β = 0.20, p = 0.001). Patients with a history of COPD (β = − 0.30, p < 0.023) or previous myocardial infarction (β = − 0.23, p = 0.041) became less frequent. Other comorbidities did not show significant trends (Table 3).Table 3 Evolution of baseline characteristics from 2016 to 2020 of patients implanted with an endocardial implanted LAA occlusion device

Patient characteristic endocardial implanted LAAC devices	2016
n = 5259	2017
n = 5271	2018
n = 5610	2019
n = 5982	2020
n = 5917	β per year	p	
Age (mean ± SD)	75.53 ± 8.06	75.84 ± 7.95	76.21 ± 8.21	76.52 ± 8.20	76.64 ± 8.28	0.29	 < 0.001	
Women	1959 (37.25%)	2093 (39.71%)	2232 (39.78%)	2273 (38.00%)	2394 (40.46%)	0.46	0.025	
Charlson Comorbidity Index	2.22 ± 1.93	2.30 ± 1.96	2.30 ± 1.94	2.31 ± 1.94	2.29 ± 1.90	0.01	ns (0.067)	
Arterial hypertension	3145 (59.80%)	3106 (58.93%)	3313 (59.06%)	3518 (58.81%)	3533 (59.71%)	− 0.02	ns	
Atrial fibrillation	5152 (97.97%)	5137 (97.46%)	5439 (96.95%)	5785 (96.71%)	5703 (96.38%)	− 0.39	 < 0.001	
Heart failure	1718 (32.67%)	1830 (34.72%)	1950 (34.94%)	2167 (36.23%)	2189 (37.00%)	1.01	 < 0.001	
Heart Failure NYHA III or IV	861 (16.37%)	969 (18.38%)	981 (17.49%)	1121 (18.74%)	1157 (19.55%)	0.67	 < 0.001	
Coronary artery disease	2472 (47.01%)	2350 (44.60%)	2564 (45.70%)	2688 (44.93%)	2676 (45.23%)	− 0.32	ns	
Previous myocardial infarction	452 (8.59%)	391 (7.42%)	458 (8.16%)	460 (7.69%)	432 (7.30%)	− 0.23	0.041	
Previous cardiac surgery	634 (12.06%)	617 (11.71%)	709 (12.64%)	774 (12.94%)	726 (12.27%)	0.16	ns	
Peripheral vascular disease	360 (6.85%)	372 (7.06%)	414 (7.38%)	402 (6.72%)	439 (7.42%)	0.08	ns	
Carotid disease	87 (1.65%)	85 (1.61%)	101 (1.80%)	110 (1.84%)	98 (1.66%)	0.02	ns	
COPD	608 (11.56%)	565 (10.72%)	624 (11.12%)	617 (10.31%)	608 (10.28%)	− 0.30	0.023	
Pulmonary hypertension	440 (8.37%)	453 (8.59%)	422 (7.52%)	504 (8.43%)	520 (8.79%)	0.08	ns	
Chronic renal disease	1927 (36.64%)	2078 (39.42%)	2165 (38.59%)	2409 (40.27%)	2342 (39.58%)	0.67	0.001	
Chronic renal disease (GFR < 60 ml/min/1.73m2)	1680 (31.95%)	1837 (34.87%)	1929 (34.39%)	2163 (36.16%)	2092 (35.36%)	0.80	 < 0.001	
Diabetes	1690 (32.14%)	1658 (31.46%)	1711 (30.50%)	1906 (31.86%)	1873 (31.65%)	− 0.04	ns	
Cancer	84 (1.60%)	102 (1.94%)	121 (2.16%)	133 (2.22%)	145 (2.45%)	0.20	0.001	
Bold and bold italic highlights significant temporal trends

LAAC Left atrial appendage closure, SD standard deviation, NYHA New York Heart Association, COPD Chronic obstructive pulmonary disease

5-year safety trends for endocardial implanted LAAC devices

In recent years new endocardial implanted occlusion devices and newer device generations were introduced to clinical practice. Therefore, we analyze the annual safety trends of the LAA plug procedures. Annual numbers of the loop stitch around the LAA base procedure were not sufficient to analyze annual trends.

For endocardial implanted LAAC devices, length of stay, rate of in-hospital mortality, MACCE, pericardial effusion, shock and resuscitation did not change significantly from 2016 to 2020. Only bleeding rates (transfusion > 5 ECs) significantly increased from 1.98% in 2015 to 2.55% in 2020 (β = 0.12, p = 0.050, Table 4). Overall, these data give no sign of in-hospital safety improvements in Germany from 2016 to 2020 for endocardial implanted LAAC device procedures.Table 4 Evolution of safety parameters from 2016 – 2020 of patients implanted with an endocardial implanted LAA occlusion device

Outcome parameters endocardial LAA occlusion device	2016
n = 5259	2017
n = 5271	2018
n = 5610	2019
n = 5982	2020
n = 5917	β per year	p	
Length of stay	6.61 ± 7.81	7.10 ± 9.13	7.12 ± 8.81	6.82 ± 8.66	6.99 ± 9.16	0.05	ns	
In-hospital mortality	59 (1.12%)	50 (0.95%)	79 (1.41%)	70 (1.17%)	66 (1.12%)	0.02	ns	
MACCE	212 (4.03%)	213 (4.04%)	224 (3.99%)	219 (3.66%)	256 (4.33%)	0.02	ns	
Myocardial infarction	94 (1.79%)	106 (2.01%)	77 (1.37%)	94 (1.57%)	123 (2.08%)	0.02	ns	
Stroke	70 (1.33%)	64 (1.21%)	80 (1.43%)	66 (1.10%)	81 (1.37%)	0.00	ns	
Bleeding (transfusion > 5 ECs)	104 (1.98%)	114 (2.16%)	133 (2.37%)	135 (2.26%)	151 (2.55%)	0.12	0.050	
Intracerebral bleeding	11 (0.19%)	17 (0.32%)	30 (0.53%)	27 (0.45%)	20 (0.34%)	0.04	ns	
Pericardial effusion	252 (4.26%)	230 (4.36%)	266 (4.74%)	295 (4.93%)	241 (4.07%)	0.01	ns	
Pericardial puncture	93 (1.58%)	114 (2.16%)	109 (1.94%)	131 (2.19%)	107 (1.81%)	0.05	ns	
Pericardiotomy	14 (0.23%)	10 (0.19%)	15 (0.27%)	13 (0.22%)	15 (0.25%)	0.01	ns	
Deep vein thrombosis	17 (0.29%)	20 (0.38%)	27 (0.48%)	25 (0.42%)	31 (0.52%)	0.05	ns	
Tachycardia	176 (2.97%)	128 (2.43%)	157 (2.80%)	189 (3.16%)	143 (2.42%)	− 0.04	ns	
Shock	100 (1.69%)	98 (1.86%)	80 (2.48%)	146 (2.44%)	115 (1.94%)	0.10	ns (0.089)	
Resuscitation	69 (1.16%)	62 (1.18%)	77 (1.37%)	76 (1.27%)	77 (1.30%)	0.04	ns	
Bold italic highlights significant temporal trends

MACCE Major adverse cardiac and cerebrovascular events, EC erythrocyte concentrate

We conducted further analysis to investigate the association between bleeding and pericardial effusion with death among patients who received an endocardial LAAC device. Patients who experienced major bleeding had a significant higher risk of death compared to those without bleeding (OR 23.34; 95% CI 18.19–29.96%; p < 0.001). Similarly, patients with pericardial effusion also had a significantly higher risk of death (OR 5.93; 95% CI 4.51–7.80%; p < 0.001) (Supplemental Tables 3, 4).

Center volume dependent outcomes of endocardial implanted LAAC devices

We then determined whether the number of endocardial LAAC procedures performed by a single center was associated with in-hospital MACCE and pericardial puncture. Our analysis revealed that neither MACCE (p = 0.083) or pericardial puncture (p = 0.080) showed any dependency on center volumes.

In-hospital safety comparison

Total numbers and relative numbers of in-hospital safety parameters regarding in-hospital mortality, MACCE, bleeding, pericardial effusion, pericardial puncture, shock and resuscitation of patients receiving the endocardial implanted LAAC device and loop stitch around the LAA base from 2016 to 2020 are given in Table 5. To compare both types of LAAC procedures we used a propensity score approach. Length of hospital stay was similar in both groups. In-hospital mortality and in-hospital MACCE showed no significant difference between the endocardial LAA plug procedure and the epicardial loop stitch procedure.Table 5 Safety parameters while hospitalization for endocardial implanted LAAC procedure and epicardial loop stitch around the LAA base procedure from 2016 – 2020

Safety parameters while hospitalization	Total procedures
n = 28,252	endocardial implanted LAA occlusion device
n = 28,039	loop stitch around the LAA base
n = 213	
Length of stay (days, mean ± SD)	6.93 ± 8.72	6.93 ± 8.74	7.33 ± 6.58	
In-hospital mortality	326 (1.15%)	325 (1.16%)	1–3 (≤ 1.41%)	
MACCE	1130 (4.00%)	1124 (4.01%)	6 (2.82%)	
Myocardial infarction	496 (1.76%)	493 (1.76%)	3 (1.41%)	
Stroke	365 (1.29%)	362 (1.29%)	3 (1.41%)	
Bleeding (transfusion > 5 ECs)	639 (2.26%)	637 (2.27%)	1–3 (≤ 1.41%)	
Intracerebral bleeding	104 (3.68%)	104 (0.37%)	0 (0.00%)	
Pericardial effusion	1289 (4.56%)	1256 (4.48%)	33 (15.49%)	
Pericardial puncture	572 (2.02%)	544 (1.94%)	28 (13.15%)	
Pericardiotomy	67 (0.24%)	64 (0.23%)	3 (1.41%)	
Deep vein thrombosis	120 (0.42%)	118 (0.42%)	1–3 (≤ 1.41%)	
Tachycardia	795 (2.81%)	774 (2.76%)	21 (9.86%)	
Shock	589 (2.08%)	586 (2.09%)	1–3 (≤ 1.41%)	
Resuscitation	355 (1.26%)	353 (1.26%)	1–3 (≤ 1.41%)	
LAA Left atrial appendage, SD standard deviation, MACCE Major adverse cardiac and cerebrovascular events (in-hospital mortality/myocardial infarction/stroke), EC erythrocyte concentrate

Risk of transfusion with more than 5 red blood cell concentrates (− 1.85%; 95% CI − 3.01 to − 0.69%; p = 0.002), intracerebral bleeding (− 0.37%; 95% CI − 0.59 to − 0.15%; p = 0.001) and shock (− 1.41%; 95% CI − 2.44 to − 0.39%; p = 0.007) was significantly lower for the loop stitch procedure, while risk of pericardial effusion (− 8.04%; 95% CI 3.01 to 13.08%; p = 0.002), pericardial puncture (6.60%; 95% CI 3.85 to 9.35%; p < 0.001) and tachycardia (− 4.32%; 95% CI 1.20 to 7.43%; p = 0.007) was significantly lower for the endocardial implanted occlusion device procedure. In-hospital risk of myocardial infarction, stroke, deep vein thrombosis and resuscitation did not show significant differences between both LAA procedure types (Fig. 2).Fig. 2 Forest plot of propensity score approach to compare adjusted risks of in-hospital safety parameters. CI confidence interval, MACCE major adverse cardiac and cerebrovascular events, EC erythrocyte concentrate

Discussion

In this real-world analysis of 28,252 patients included we present a nation-wide dataset of procedure numbers and safety trends of catheter based LAA closure procedures for all patients treated in Germany from 2016 to 2020. An endocardial implanted LAA occlusion device was the most frequently used LAAC procedure in this period in Germany while a loop stitch around the LAA base was done rarely. Safety parameters did not show significant trends for the endocardial implanted occlusion device from 2016 to 2020 except of an increase in bleeding rates.

In-hospital mortality and in-hospital MACCE did not show significant differences between both procedures while the loop stitch around the LAA procedure was associated with more tachycardia, pericardial effusion and pericardial punctures and the endocardial implanted LAA occlusion device procedure with more bleeding, intracerebral bleeding and shock.

The lack of any signal for an improvement in procedural safety is somewhat surprising. Newer generations of endocardial LAA occlusion devices were introduced in the clinical routine from 2013. The second generation Watchman FLX received a first CE mark in 2015 but was retracted from the market and has got a new CE mark since 2019. The second generation Watchman FLX (Boston Scientific) finally received the CE mark in 2019. Amulet (Abbott), the second generation Amplatzer occluder, has got a CE mark since 2013. Other newer occluders like WaveCrest (Biosense) or Occlutech (Occlutech) received the CE mark in 2013 and 2016, respectively [20].

The second generation Watchman device had low procedural complication rates in a multicenter registry with 165 patients [24] similar to a randomized multicenter industry sponsored trial comparing the first and second Watchman generations which found a very low incidence of adverse events for both generations [25]. Clinical outcomes at 45 days did not differ between Amulet and Watchman in the randomized multicenter industry supported SWISS APERO trial with 221 patients. This study did also not find clear evidence that the newer Watchman FLX provides superior LAA sealing compared with the earlier-generation [26]. The data of the here presented study show no signal of in-hospital safety improvements in a 5-year period after the introduction of new LAA occluder generations. In fact, in-hospital safety remained on a similar level as reported in an earlier real-world study by Hobohm et al. [12], who investigated safety trends for LAA occlusion in Germany from 2011 to 2015. Total procedure numbers increased from 1347 in 2011 to 4932 in 2015 to 5917 in 2020. Most patient characteristics were similar in the 2016 to 2020 and 2011 to 2015 cohort, with the exception of chronic renal disease, which was evident more frequently in the 2016 to 2020 cohort. Safety trends for the endocardial implanted device from 2016 to 2020 remained similar compared with the cohort from 2011 to 2015: In-hospital mortality remained in a range from 0.9 to 1.4% from 2013 to 2020. MACCE was similar in both studies. Also, pericardial effusion and pericardial puncture rates in our endocardial implanted occlusion device group were similar to the 2011 to 2015 data. Similar invasive procedures such as atrial fibrillation ablation are associated with comparable pericardial effusion rates of 1 to 6% [12, 27, 28].

The overall rate of transfusion > 5 ECs after LAAC in Germany was 2.26% from 2016 to 2020. Newer short term analyses of bleeding rates after Watchman FLX implantation report approximately 3% [24, 25]. The SWISS APERO trial reported major bleeding of 7.2% for the Amulet device and 1.8% for the Watchman occluder at 45 days after implantation [26]. A Canadian registry reported 4.7% major bleeding implantation within 7 days after Watchman implantation [8], a European registry reported 0.9% major bleeding within 7 days after Watchman implantation [11]. Another real world analysis of LACC in Germany from 2011 to 2015 reported transfusion rates of 10% [12]. Reasons for different bleeding rates might be heterogenous patient populations, different definitions of (major) bleeding and reporting time frames.

The endocardial implanted LAAC procedure was preferred in Germany from 2016 to 2020. One reason might be a longer history of experience and training with this type of occluder. Another possible reason could be the higher complexity of the invasive loop stitch technique which requires a combination of transseptal puncture and pericardial access.

ESC guidelines state that for patients who do not tolerate any antiplatelet therapy, an epicardial catheter approach (e.g. Lariat) may be an option [1, 29, 30]. Our data show, that the loop stitch procedure was associated with a significantly lower risk of bleeding. In contrast to the endocardial implanted LAA occlusion devices, which are usually treated with single or dual antiplatelet therapy for a period of several months [6, 24], the epicardial catheter approach usually does not need antiplatelet therapy. Our analysis supports the recommendation that patients with high bleeding risk from antiplatelet therapy can be considered for the epicardial loop stitch procedure.

To our knowledge, this is the first study comparing in-hospital safety of the widely used endocardial implanted plug occlusion devices and a loop stitch procedure around the LAA base in a head-to-head fashion. This real world data can be regarded as free of study selection bias, as all patients reimbursed in Germany were analyzed. More pericardial effusion and necessity of pericardial puncture for the LAA loop stitch procedure is likely caused by pericardial puncture during the procedure. Conversely, higher rates of bleeding and shock were present in patients implanted with an endocardial LAAC device.

The Lariat device is the only currently available epicardial LAAC procedure. Few reports about Lariat safety exist but none of them compares the Lariat device with other procedure types [31]. These studies report heterogenous results. In a multicenter study by Parik et al. with 108 patients implanted with Lariat no procedure related mortality was evident but 1.09% of the patients needed open heart surgery, 2.8% had cardiac perforation without the need of surgery and 1.9% needed transfusion [32]. Another multicenter trial by Tilz et al. with 141 patients reported a serious adverse event rate of 2.8% [33]. A study by Fink et al. with 44 patients undergoing successful LAA ligation with Lariat found an incidence of major periprocedural complications of 6%, and a significant rate of incomplete LAA ligation during follow-up. They suggest that epicardial LAA ligation should only be performed in selected patients and in centers with experience in dry epicardial puncture and on-site cardiac surgery [34, 35]. Overall, due to the technically challenging procedure and complications it was believed to be unlikely that Lariat would capture market share compared with endocardial occlusion systems. However, refining the technique and new benefits of LAA ligation made the community reconsider this [18]. In hypertensive AF patients, epicardial LAA occlusion significantly decreased systolic blood pressure compared with endocardial LAAC [36]. A prospective, multicenter, randomized controlled trial was initiated to evaluate the safety and effectiveness of the Lariat system to percutaneously isolate and ligate the left atrial appendage from the left atrium as an adjunct to pulmonary vein isolation in the treatment of subjects with symptomatic persistent or longstanding persistent atrial fibrillation (aMAZE, ClinicalTrials.gov Identifier: NCT02513797). This trial showed that LAA ligation with Lariat plus pulmonary vein isolation was not superior at preventing recurrent atrial fibrillation compared with pulmonary vein isolation alone. Exploratory analysis of this study suggested that possible benefits among patients with early persistent atrial fibrillation and large left atrial volumes, which both needs to be further investigated.

We did not particularly investigate the influence of the COVID-19 pandemic [37–39] starting in January 2020 on the LAA occlusion numbers and patient selection in Germany [40]. In 2020 the total procedure numbers slightly decreased to 5917 from a high of 6019 procedures in 2019. Further analysis of the period from 2020 to 2022 is warranted to clarify COVID-19 impact. Data on this will be expected in 2024.

Study limitations

Our study has several limitations. First, the ICD discharge code based data collection used for our analysis is potentially biased by under- or overreporting. It is very unlikely that the here used end-points like in-hospital MACCE were under-reported, as an increase in resource-utilization often triggers an additional reimbursement. It is also not reported at what time of the hospital stay an outcome event occurred or if it’s associated with a procedure other than LAAC of the same hospital stay. In the German reimbursement system it is unlikely that a second major procedure (e.g. coronary angiography) is carried out during the same hospitalization as LAAC. Second, we cannot address long-term outcomes with ICD discharge codes. Third, we cannot distinguish between different endocardial implanted occlusion devices and indications that all use the same OPS-code. Fourth, the HAS BLED score cannot be calculated with ICD codes [41, 42]. Fifth, the entire endpoint set from the Munich consensus document for LAAC cannot be covered with ICD and OPS codes and had therefore be simplified [43]. Last, a selection bias for the loop stitch procedure patients is likely and limit the comparison to the large cohort treated with the endocardial devices.

Conclusions

In Germany, numbers of catheter based LAAC increased from 5307 in 2016 to 5952 in 2020. In the majority of cases the catheter based LAAC was performed with an endocardial implanted LAA occlusion device. An epicardial loop stitch procedure around the base of the LAA was carried out rarely. The LAA loop stitch procedure was associated with higher risk of pericardial effusion and pericardial puncture while the plug procedure was associated with a higher risk of bleeding, intracerebral bleeding and shock. Our analysis supports the recommendation that patients with a high bleeding risk from antiplatelet therapy can be considered for the epicardial loop stitch procedure, but that this should be reserved for these very selected cases. Furthermore, these data show no sign of in-hospital safety improvements for endocardial implanted LAAC devices from 2016 to 2020.

Supplementary Information

Below is the link to the electronic supplementary material.Supplementary file1 (DOCX 350 KB)

Abbreviations

LAA Left atrial appendage

LAAC Left atrial appendage closure

OAC Oral anticoagulation

CE Conformité Européenne

MACCE Major adverse cardiac and cerebrovascular events

COPD Chronic obstructive pulmonary disease

EC Erythrocyte concentrate

CI Confidence interval

NYHA New York Heart Association

Acknowledgements

AM was funded by the Berta-Ottenstein-Programme for Advanced Clinician Scientists, Faculty of Medicine, University of Freiburg. AM, TH, DW and CvzM are members of SFB1425, funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)—Project #422681845. We thank Diana Chiang Jurado for kindly proofreading our manuscript. The data underlying this article are available in the article and in its online supplementary material.

Author contributions

AM designed the study, interpreted data and drafted the manuscript. KK designed the study, performed statistical analysis, interpreted data and drafted the manuscript. SG and CvzM designed the study, interpreted data and proofread the manuscript. TH and DW interpreted data and proofread the manuscript.

Funding

Open Access funding enabled and organized by Projekt DEAL. AM was funded by the Berta-Ottenstein-Programme for Advanced Clinician Scientists, Faculty of Medicine, University of Freiburg. The authors declare that there is no conflict of interest.

Declarations

Conflict of interest

The authors declare that there is no conflict of interest.

Constantin von zur Mühlen and Sebastian Grundmann contributed equally.
==== Refs
References

1. Hindricks G 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Eur Heart J 2021 42 373 498 10.1093/eurheartj/ehaa612 32860505
Hindricks G et al (2021) 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 42:373–49832860505
2. Ding WY Outcomes of left atrial appendage occlusion vs. non-vitamin K antagonist oral anticoagulants in atrial fibrillation Clin Res Cardiol 2022 111 1040 1047 10.1007/s00392-021-01983-z 34994832
Ding WY et al (2022) Outcomes of left atrial appendage occlusion vs. non-vitamin K antagonist oral anticoagulants in atrial fibrillation. Clin Res Cardiol 111:1040–104734994832
3. Haas S GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide Clin Res Cardiol 2023 112 759 771 10.1007/s00392-022-02079-y 36094573
Haas S et al (2023) GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide. Clin Res Cardiol 112:759–77136094573
4. Hart RG Pearce LA Aguilar MI Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 2007 146 857 867 10.7326/0003-4819-146-12-200706190-00007 17577005
Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:857–86717577005
5. Reddy VY Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology) J Am Coll Cardiol 2013 61 2551 2556 10.1016/j.jacc.2013.03.035 23583249
Reddy VY et al (2013) Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol 61:2551–255623583249
6. Boersma LVA Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry Eur Heart J 2016 37 2465 2474 10.1093/eurheartj/ehv730 26822918
Boersma LVA et al (2016) Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J 37:2465–247426822918
7. Teiger E Percutaneous left atrial appendage closure is a reasonable option for patients with atrial fibrillation at high risk for cerebrovascular events Circ Cardiovasc Interv 2018 11 e005841 10.1161/CIRCINTERVENTIONS.117.005841 29540492
Teiger E et al (2018) Percutaneous left atrial appendage closure is a reasonable option for patients with atrial fibrillation at high risk for cerebrovascular events. Circ Cardiovasc Interv 11:e00584129540492
8. Saw J Early Canadian multicenter experience with WATCHMAN for percutaneous left atrial appendage closure J Cardiovasc Electrophysiol 2017 28 396 401 10.1111/jce.13168 28128883
Saw J et al (2017) Early Canadian multicenter experience with WATCHMAN for percutaneous left atrial appendage closure. J Cardiovasc Electrophysiol 28:396–40128128883
9. Gerçek M Börgermann J Gummert J Gerçek M Five-year-outcome of new-onset perioperative atrial fibrillation after left atrial appendage amputation concomitant with cardiac surgery Clin Res Cardiol 2023 10.1007/s00392-023-02255-8 37428220
Gerçek M, Börgermann J, Gummert J, Gerçek M (2023) Five-year-outcome of new-onset perioperative atrial fibrillation after left atrial appendage amputation concomitant with cardiac surgery. Clin Res Cardiol. 10.1007/s00392-023-02255-837428220
10. Ancona DG Left atrial appendage closure with the watchman device reduces atrial fibrillation management costs Clin Res Cardiol 2022 111 105 113 10.1007/s00392-021-01943-7 34652527
Ancona DG et al (2022) Left atrial appendage closure with the watchman device reduces atrial fibrillation management costs. Clin Res Cardiol 111:105–11334652527
11. Boersma LV Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial Heart Rhythm 2017 14 1302 1308 10.1016/j.hrthm.2017.05.038 28577840
Boersma LV et al (2017) Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial. Heart Rhythm 14:1302–130828577840
12. Hobohm L 5-year experience of in-hospital outcomes after percutaneous left atrial appendage closure in Germany JACC Cardiovasc Intervent 2019 12 1044 1052 10.1016/j.jcin.2019.04.002
Hobohm L et al (2019) 5-year experience of in-hospital outcomes after percutaneous left atrial appendage closure in Germany. JACC Cardiovasc Intervent 12:1044–1052
13. Kany S Impact of atrial fibrillation pattern on outcomes after left atrial appendage closure: lessons from the prospective LAARGE registry Clin Res Cardiol 2022 111 511 521 10.1007/s00392-021-01874-3 34043052
Kany S et al (2022) Impact of atrial fibrillation pattern on outcomes after left atrial appendage closure: lessons from the prospective LAARGE registry. Clin Res Cardiol 111:511–52134043052
14. Vij V Symptomatic vs. non-symptomatic device-related thrombus after LAAC: a sub-analysis from the multicenter EUROC-DRT registry Clin Res Cardiol 2023 10.1007/s00392-023-02237-w 37294311
Vij V et al (2023) Symptomatic vs. non-symptomatic device-related thrombus after LAAC: a sub-analysis from the multicenter EUROC-DRT registry. Clin Res Cardiol. 10.1007/s00392-023-02237-w37294311
15. Vij V Clinical and echocardiographic risk factors for device-related thrombus after left atrial appendage closure: an analysis from the multicenter EUROC-DRT registry Clin Res Cardiol 2022 111 1276 1285 10.1007/s00392-022-02065-4 35849156
Vij V et al (2022) Clinical and echocardiographic risk factors for device-related thrombus after left atrial appendage closure: an analysis from the multicenter EUROC-DRT registry. Clin Res Cardiol 111:1276–128535849156
16. Badheka AO Utilization and adverse outcomes of percutaneous left atrial appendage closure for stroke prevention in atrial fibrillation in the United States: influence of hospital volume Circ Arrhythm Electrophysiol 2015 8 42 48 10.1161/CIRCEP.114.001413 25480543
Badheka AO et al (2015) Utilization and adverse outcomes of percutaneous left atrial appendage closure for stroke prevention in atrial fibrillation in the United States: influence of hospital volume. Circ Arrhythm Electrophysiol 8:42–4825480543
17. Fauchier L Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation J Am Coll Cardiol 2018 71 1528 1536 10.1016/j.jacc.2018.01.076 29622159
Fauchier L et al (2018) Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation. J Am Coll Cardiol 71:1528–153629622159
18. O’Neill WW The lariat device J Am Coll Cardiol 2018 72 1354 1356 10.1016/j.jacc.2018.07.019 30213327
O’Neill WW (2018) The lariat device. J Am Coll Cardiol 72:1354–135630213327
19. Bartus K Feasibility of closed-chest ligation of the left atrial appendage in humans Heart Rhythm 2011 8 188 193 10.1016/j.hrthm.2010.10.040 21050893
Bartus K et al (2011) Feasibility of closed-chest ligation of the left atrial appendage in humans. Heart Rhythm 8:188–19321050893
20. Narasimhan B Current practice and future prospects in left atrial appendage occlusion Pacing Clin Electrophysiol 2021 44 1236 1252 10.1111/pace.14284 34085712
Narasimhan B et al (2021) Current practice and future prospects in left atrial appendage occlusion. Pacing Clin Electrophysiol 44:1236–125234085712
21. Gunda S Differences in complication rates between large bore needle and a long micropuncture needle during epicardial access: time to change clinical practice? Circ Arrhythm Electrophysiol 2015 8 890 895 10.1161/CIRCEP.115.002921 26078278
Gunda S et al (2015) Differences in complication rates between large bore needle and a long micropuncture needle during epicardial access: time to change clinical practice? Circ Arrhythm Electrophysiol 8:890–89526078278
22. Greenbaum AB Intentional Right Atrial Exit and Carbon Dioxide Insufflation to Facilitate Subxiphoid Needle Entry Into the Empty Pericardial Space: First Human Experience JACC Clin Electrophysiol 2015 1 434 441 10.1016/j.jacep.2015.06.007 26618198
Greenbaum AB et al (2015) Intentional Right Atrial Exit and Carbon Dioxide Insufflation to Facilitate Subxiphoid Needle Entry Into the Empty Pericardial Space: First Human Experience. JACC Clin Electrophysiol 1:434–44126618198
23. Glasheen WP Charlson Comorbidity Index: ICD-9 Update and ICD-10 Translation Am Health Drug Benefits 2019 12 188 197 31428236
Glasheen WP et al (2019) Charlson Comorbidity Index: ICD-9 Update and ICD-10 Translation. Am Health Drug Benefits 12:188–19731428236
24. Cruz-González I Procedural and short-term results with the new watchman FLX left atrial appendage occlusion device JACC Cardiovasc Interv 2020 13 2732 2741 10.1016/j.jcin.2020.06.056 33189641
Cruz-González I et al (2020) Procedural and short-term results with the new watchman FLX left atrial appendage occlusion device. JACC Cardiovasc Interv 13:2732–274133189641
25. Kar S Primary outcome evaluation of a next-generation left atrial appendage closure device: results from the PINNACLE FLX trial Circulation 2021 143 1754 1762 10.1161/CIRCULATIONAHA.120.050117 33820423
Kar S et al (2021) Primary outcome evaluation of a next-generation left atrial appendage closure device: results from the PINNACLE FLX trial. Circulation 143:1754–176233820423
26. Galea R Amulet or watchman device for percutaneous left atrial appendage closure: primary results of the SWISS-APERO randomized clinical trial Circulation 2022 145 724 738 10.1161/CIRCULATIONAHA.121.057859 34747186
Galea R et al (2022) Amulet or watchman device for percutaneous left atrial appendage closure: primary results of the SWISS-APERO randomized clinical trial. Circulation 145:724–73834747186
27. Cappato R Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation Circ Arrhythm Electrophysiol 2010 3 32 38 10.1161/CIRCEP.109.859116 19995881
Cappato R et al (2010) Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 3:32–3819995881
28. Calkins H et al. (2007) HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Personnel, Policy, Procedures and Follow-Up: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation Developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Endorsed and Approved by the governing bodies of the American College of Cardiology, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, and the Heart Rhythm Society. EP Europace 9:335–379
29. Lakkireddy D Short and long-term outcomes of percutaneous left atrial appendage suture ligation: results from a US multicenter evaluation Heart Rhythm 2016 13 1030 1036 10.1016/j.hrthm.2016.01.022 26872554
Lakkireddy D et al (2016) Short and long-term outcomes of percutaneous left atrial appendage suture ligation: results from a US multicenter evaluation. Heart Rhythm 13:1030–103626872554
30. van Laar C Thoracoscopic left atrial appendage clipping: a multicenter cohort analysis JACC Clin Electrophysiol 2018 4 893 901 10.1016/j.jacep.2018.03.009 30025689
van Laar C et al (2018) Thoracoscopic left atrial appendage clipping: a multicenter cohort analysis. JACC Clin Electrophysiol 4:893–90130025689
31. Litwinowicz R Reduction in risk of stroke and bleeding after left atrial appendage closure with LARIAT device in patients with increased risk of stroke and bleeding: Long term results Catheter Cardiovasc Interv 2019 94 837 842 10.1002/ccd.28187 30884101
Litwinowicz R et al (2019) Reduction in risk of stroke and bleeding after left atrial appendage closure with LARIAT device in patients with increased risk of stroke and bleeding: Long term results. Catheter Cardiovasc Interv 94:837–84230884101
32. Parikh V Long-term clinical outcomes from real-world experience of left atrial appendage exclusion with LARIAT device J Cardiovasc Electrophysiol 2019 30 2849 2857 10.1111/jce.14229 31596044
Parikh V et al (2019) Long-term clinical outcomes from real-world experience of left atrial appendage exclusion with LARIAT device. J Cardiovasc Electrophysiol 30:2849–285731596044
33. Tilz RR A collective European experience with left atrial appendage suture ligation using the LARIAT+ device Europace 2020 22 924 931 10.1093/europace/euaa004 32044994
Tilz RR et al (2020) A collective European experience with left atrial appendage suture ligation using the LARIAT+ device. Europace 22:924–93132044994
34. Fink T Acute and long-term outcomes of epicardial left atrial appendage ligation with the second-generation LARIAT device: a high-volume electrophysiology center experience Clin Res Cardiol 2018 107 1139 1147 10.1007/s00392-018-1288-1 29881879
Fink T et al (2018) Acute and long-term outcomes of epicardial left atrial appendage ligation with the second-generation LARIAT device: a high-volume electrophysiology center experience. Clin Res Cardiol 107:1139–114729881879
35. Fink T Correction to: Acute and long-term outcomes of epicardial left atrial appendage ligation with the second-generation LARIAT device: a high-volume electrophysiology center experience Clin Res Cardiol 2018 107 1196 1196 10.1007/s00392-018-1322-3 29968195
Fink T et al (2018) Correction to: Acute and long-term outcomes of epicardial left atrial appendage ligation with the second-generation LARIAT device: a high-volume electrophysiology center experience. Clin Res Cardiol 107:1196–119629968195
36. Turagam MK Epicardial left atrial appendage exclusion reduces blood pressure in patients with atrial fibrillation and hypertension J Am Coll Cardiol 2018 72 1346 1353 10.1016/j.jacc.2018.06.066 30213326
Turagam MK et al (2018) Epicardial left atrial appendage exclusion reduces blood pressure in patients with atrial fibrillation and hypertension. J Am Coll Cardiol 72:1346–135330213326
37. Bemtgen X Myocarditis mortality with and without COVID-19: insights from a national registry Clin Res Cardiol 2022 10.1007/s00392-022-02141-9 36565377
Bemtgen X et al (2022) Myocarditis mortality with and without COVID-19: insights from a national registry. Clin Res Cardiol. 10.1007/s00392-022-02141-936565377
38. Oettinger V COVID-19 pandemic affects STEMI numbers and in-hospital mortality: results of a nationwide analysis in Germany Clin Res Cardiol 2023 112 550 557 10.1007/s00392-022-02102-2 36198827
Oettinger V et al (2023) COVID-19 pandemic affects STEMI numbers and in-hospital mortality: results of a nationwide analysis in Germany. Clin Res Cardiol 112:550–55736198827
39. Zeymer U Effects of the COVID-19 pandemic on acute coronary syndromes in Germany during the first wave: the COVID-19 collateral damage study Clin Res Cardiol 2023 112 539 549 10.1007/s00392-022-02082-3 35978111
Zeymer U et al (2023) Effects of the COVID-19 pandemic on acute coronary syndromes in Germany during the first wave: the COVID-19 collateral damage study. Clin Res Cardiol 112:539–54935978111
40. Slagman A Medical and cardio-vascular emergency department visits during the COVID-19 pandemic in 2020: is there a collateral damage? A retrospective routine data analysis Clin Res Cardiol 2022 111 1174 1182 10.1007/s00392-022-02074-3 35931896
Slagman A et al (2022) Medical and cardio-vascular emergency department visits during the COVID-19 pandemic in 2020: is there a collateral damage? A retrospective routine data analysis. Clin Res Cardiol 111:1174–118235931896
41. Stachon P Coronary artery bypass grafting versus stent implantation in patients with chronic coronary syndrome and left main disease: insights from a register throughout Germany Clin Res Cardiol 2022 111 742 749 10.1007/s00392-021-01931-x 34453576
Stachon P et al (2022) Coronary artery bypass grafting versus stent implantation in patients with chronic coronary syndrome and left main disease: insights from a register throughout Germany. Clin Res Cardiol 111:742–74934453576
42. Ledwoch J Impact of HAS-BLED Score on outcome after percutaneous left atrial appendage closure: insights from the German Left Atrial Appendage Occluder Registry LAARGE Clin Res Cardiol 2022 111 541 547 10.1007/s00392-021-01911-1 34455462
Ledwoch J et al (2022) Impact of HAS-BLED Score on outcome after percutaneous left atrial appendage closure: insights from the German Left Atrial Appendage Occluder Registry LAARGE. Clin Res Cardiol 111:541–54734455462
43. Tzikas A Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies EP Europace 2017 19 4 15 27540038
Tzikas A et al (2017) Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies. EP Europace 19:4–1527540038
